02.12.15
Hospira
4Q Revenues: $1.1 billion (+4%)
4Q Earnings: $35.8 million (+7%)
FY Revenues: $4.5 billion (+12%)
FY Earnings: $333.2 million (loss of $8.3 million FY13)
Comments: Growth in the quarter was driven by U.S. Specialty Injectable Pharmaceuticals (SIP), up 6% to $606.8 million, and Other Pharma sales, up 24% $130.1 million, offset by the expected decline of Precedex, docetaxel and Medication Management sales, related to the divestiture of the TheraDoc clinical surveillance software business. Global SIP sales in the quarter were $752.8 million, up 3%, and Other Pharma sales were $163.0 million, up 25%. In the quarter, Pfizer entered into a definitive merger agreement to acquire Hospira for approximately $17 billion.
4Q Revenues: $1.1 billion (+4%)
4Q Earnings: $35.8 million (+7%)
FY Revenues: $4.5 billion (+12%)
FY Earnings: $333.2 million (loss of $8.3 million FY13)
Comments: Growth in the quarter was driven by U.S. Specialty Injectable Pharmaceuticals (SIP), up 6% to $606.8 million, and Other Pharma sales, up 24% $130.1 million, offset by the expected decline of Precedex, docetaxel and Medication Management sales, related to the divestiture of the TheraDoc clinical surveillance software business. Global SIP sales in the quarter were $752.8 million, up 3%, and Other Pharma sales were $163.0 million, up 25%. In the quarter, Pfizer entered into a definitive merger agreement to acquire Hospira for approximately $17 billion.
